Regeneron Pharmaceuticals (REGN) is back in focus after Japan approved Dupixent as the first targeted treatment for adults ...
Sanofi (ENXTPA:SAN) has drawn fresh attention after positive phase 3 data for amlitelimab in atopic dermatitis and Japanese ...
Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn more about SNY stock here.
Piper Sandler has initiated Regeneron Pharmaceuticals (REGN) at overweight saying that it expects continued growth in Dupixent (dupilumab) sales as well as "several high-potential pipeline assets." ...
Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported lower-than-expected profits after outlaying money to develop new treatments. Dupixent ...
Sanofi SNY and partner Regeneron REGN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (“CSU”) in adults and adolescents aged 12 years and above, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results